Evidence map›Paper›PMID 34698997›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years-single institution experience.

I Membrive Conejo, O Pera Cegarra, P Foro Arnalot, A Reig Castillejo, N Rodríguez de Dios, X Sanz Latiesas, G Deza, J Quera Jordana, E Fernandez-Velilla Cepria, A Martínez Moñino and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Iodine-125 plesiotherapy for murine tumor treatment.Radiation oncology (London, England) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

I Membrive ConejoRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain. imembrive@parcdesalutmar.cat.ORCID http://orcid.org/0000-0003-3113-7475
O Pera CegarraRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
P Foro ArnalotRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
A Reig CastillejoRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
N Rodríguez de DiosRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
X Sanz LatiesasRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
G DezaInstitut Hospital del Mar d'Investigacions Mèdiques Barcelona, Barcelona, Spain.
J Quera JordanaRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
E Fernandez-Velilla CepriaRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
A Martínez MoñinoRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
F Liu ChengRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
M Algara LópezRadiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Passeig Marítim 25, 08003, Barcelona, Spain.
Parc de Salut · ESUniversitat Pompeu Fabra · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur center adopted high-dose-rate brachytherapy with surface applicators (plesiotherapy) in 2008, creating custom molds to treat irregular areas. This study describes the efficacy and safety outcomes after extensive follow-up in the patients. METHODS/PATIENTS: We planned the treatment using two computed tomography (CT) scans: the first to delineate the lesion and the second after placing the thermoplastic mold. Fusing the two CT images enables planning of the target volume and pinpointing, where the catheters are in the mold.

resultsSeventy patients received plesiotherapy, either exclusively or following excision in patients with risk factors for recurrence. Those receiving plesiotherapy alone showed a complete response rate of 95.8%, and recurrences occurred in 5.7% at a mean follow-up of 96.2 months. Chronic toxicity appeared in 26.6% of patients, but severity was limited to grade 1 or 2.

conclusionsHigh-dose-rate brachytherapy with customized molds yields a high rate of complete response, with long-term recurrence rates in line with similar studies and an acceptable toxicity rate.

Indexed as

AgedAged, 80 and overBrachytherapyEquipment DesignFemaleHumansMaleMiddle AgedRetrospective StudiesSkin NeoplasmsTime FactorsTreatment OutcomeBrachytherapyCustom moldsPlesiotherapySkin cancer

Identifiers

PMID34698997
PMCPMC8885494
OpenAlexW3210190558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.